Miniatura

Fitxers

683951.pdf (2.9 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-11-01

Llicència de publicació

cc by-nc (c) Sanjosé Llongueras et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172145

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/jncics/pky045

Resum

Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.

Matèries

Papil·lomavirus, Càncer de coll uterí

Matèries (anglès)

Papillomaviruses, Cervix cancer

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
<b>Publicacions de projectes de recerca finançats per la UE</b>
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SANJOSÉ LLONGUERAS, Silvia de, SERRANO, Beatriz, TOUS, Sara, ALEJO, Maria, LLOVERAS RUBIO, Betlem, QUIRÓS, Beatriz, CLAVERO, Omar, VIDAL-BEL, August, FERRÁNDIZ PULIDO, Carla, PAVÓN RIBAS, Miquel àngel, HOLZINGER, Dana, HALEC, Gordana, TOMMASINO, Massimo, QUINT, Wim, PAWLITA, Michael, MUÑOZ, Nubia, BOSCH JOSÉ, Francesc xavier, ALEMANY I VILCHES, Laia, RIS HPV TT, Vvap and head and neck study groups. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. _JNCI Cancer Spectrum_. 2018. Vol. 2, núm. 4, pàgs. pky045. [consulta: 23 de gener de 2026]. ISSN: 2515-5091. [Disponible a: https://hdl.handle.net/2445/172145]

Exportar metadades

JSON - METS

Compartir registre